Wednesday, September 06, 2017 3:37:49 PM
The below items are just my thoughts , I dont know how accurate these points are
1) if CIAB platform works for oncology , diabetes, human and veterinary , then the platform may be valuable to a Big P . I expect the big P would want total control and buy PMCB + SGA + have a new agreement with Bavarian Nordic for the rights to the special SCS (sodium cellulose sulfate material which makes up CIAB capsules)
2) pmcb HAS APPLIED FOR A NEW PATENT ( Spring 2017) FOR CIAB + P450 genetically modified cells for treatment to activate a pro-drug to treat solid tumors ... I do not know the status of this patent ,
but I suppose we do have orphan drug designation to protect our treatment exclusivity for 7 years / 10 years in Europe
3) PMCB has "X" number of years to make clinical use of CIAB , otherwise rights revert back to SGA and Bavarian Nordic
4) I am not sure , but I believe the SCS sodium cellulose sulfate material may no longer be patent protected , and that PMCB no longer owes any payment to Bavarian Nordic
5) maybe Yuen ( PrimeGen) will see a real possibility with CIAB platform , and PMCB + SGA will agree to M&A with Yuen , re-structured , and up-list to NASDQ after a successful Pivotal Trial , and plan to fulfill the treatment demand for product , to treat all solid tumors
6) re Diabetes, it does seem as though encapsulated cells are the next big improvement for treatment . Harvard has developed stem cells , and we have our Melligen cells , Regardless of wjhich cell type works best , and lives the longest , it seems our SCS cotton micro capsules are the best thing going for beating the immune response .
1) if CIAB platform works for oncology , diabetes, human and veterinary , then the platform may be valuable to a Big P . I expect the big P would want total control and buy PMCB + SGA + have a new agreement with Bavarian Nordic for the rights to the special SCS (sodium cellulose sulfate material which makes up CIAB capsules)
2) pmcb HAS APPLIED FOR A NEW PATENT ( Spring 2017) FOR CIAB + P450 genetically modified cells for treatment to activate a pro-drug to treat solid tumors ... I do not know the status of this patent ,
but I suppose we do have orphan drug designation to protect our treatment exclusivity for 7 years / 10 years in Europe
3) PMCB has "X" number of years to make clinical use of CIAB , otherwise rights revert back to SGA and Bavarian Nordic
4) I am not sure , but I believe the SCS sodium cellulose sulfate material may no longer be patent protected , and that PMCB no longer owes any payment to Bavarian Nordic
5) maybe Yuen ( PrimeGen) will see a real possibility with CIAB platform , and PMCB + SGA will agree to M&A with Yuen , re-structured , and up-list to NASDQ after a successful Pivotal Trial , and plan to fulfill the treatment demand for product , to treat all solid tumors
6) re Diabetes, it does seem as though encapsulated cells are the next big improvement for treatment . Harvard has developed stem cells , and we have our Melligen cells , Regardless of wjhich cell type works best , and lives the longest , it seems our SCS cotton micro capsules are the best thing going for beating the immune response .
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
